Legislative Activity

Oppose the Modernizing Opioid Treatment Access (MOTA) Act

We understand that there are different perspectives in having practitioners prescribe methadone to treat opioid use disorder outside of the scope of OTPs. There are several issues that merit consideration.

We are providing links to five published reports on methadone mortality. They were published between 2003 and 2010. The conclusion of all five reports was that methadone mortality increased sharply between 1999 and 2010 as a direct result of methadone being prescribed for pain by medical practitioners and that these prescriptions were filled by local pharmacies. These reports, in part, form the basis of our concern.

It is also important to keep in mind how the prescription of opioids to manage pain sparked the current opioid epidemic, which morphed from the use of prescription opioids to intravenous heroin use and more recently to fentanyl use.

There are also some misconceptions about the safety of providing significant take-home medication during COVID-19. We are providing links to two recently published articles, listed below. We will certainly learn more about this in the coming year as more information becomes available. We support SAMHSA’S recommended regulatory changes and we are sharing our formal response to SAMHSA, click HERE.

Finally, the Association’s paper, released on March 2, 2002, provides a broad perspective with regard to our policy initiatives.
Regulatory Reform and Policy Initiatives for OTPs in a Post Covid- 19 World

We hope that this helps to answer a number of inquiries that we have received through our social media platforms.

Twitter feed is not available at the moment.

#aatod2022 conference

225 Varick Street, Suite 402
New York, New York 10014

Contact Us
Phone : 212-566-5555
Email : info@aatod.org

Social Sharing
Follow by Email

Stay Connected to AATOD